D'Arienzo Celia J, Ji Qin C, Discenza Lorell, Cornelius Georgia, Hynes John, Cornelius Lyndon, Santella Joseph B, Olah Timothy
Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, USA.
Bioanalysis. 2010 Aug;2(8):1415-22. doi: 10.4155/bio.10.94.
Prodrugs that exhibit ex vivo instability owing to high levels of esterases in rodent blood, plasma and serum present challenges in the accurate determination of drug exposure in samples from pharmacokinetic, pharmacokinetic/pharmacodynamic, efficacy and toxicology studies in drug discovery. Ensuring the stability of analytes in sample collection, handling, analysis and storage must be established for program progression. Current protocols for the stabilization of prodrugs include the immediate quenching of whole blood with acetonitrile or methanol to stop enzyme activity, or the addition of an esterase inhibitor such as phenylmethanesulfonyl fluoride to the blood collection tubes before serum or plasma is generated. Dried blood spots (DBS) sampling may offer an alternative prodrug stabilization method for sample collection and storage from rodent studies in drug discovery.
Two different prodrugs of the same parent compound that were known to exhibit ex vivo instability in rodent blood were selected for the evaluation of DBS for analyte stabilization. Each prodrug was spiked separately into fresh rat EDTA whole blood and prepared three ways: from liquid whole blood, prepared and analyzed as lysate; from whole blood spotted onto Whatman 903(®) Protein Saver untreated cards (903 cards); and from whole blood spotted onto Whatman FTA(®) Elute Micro treated cards, currently known as DMPK-B cards (FTA cards). Samples were extracted by filtration-assisted protein precipitation at 0, 2, 5 and 24 h and 4, 7, 14 and 21 days after spiking and analyzed by UHPLC-MS/MS.
For these two prodrugs, stability on DBS cards was observed in rat EDTA whole blood for at least 21 days at room temperature as determined by loss of prodrug and appearance of parent. The Whatman FTA Elute cards, treated with reagents that lyse cells, did not offer more stability for the investigated compounds than the Whatman 903 Protein Saver untreated cards.
由于啮齿动物血液、血浆和血清中酯酶水平较高而表现出体外不稳定性的前体药物,在药物发现阶段的药代动力学、药代动力学/药效学、疗效和毒理学研究中,准确测定样品中的药物暴露量面临挑战。为确保项目进展,必须确定在样品采集、处理、分析和储存过程中分析物的稳定性。目前用于稳定前体药物的方案包括用乙腈或甲醇立即淬灭全血以停止酶活性,或在生成血清或血浆之前向采血管中添加酯酶抑制剂,如苯甲基磺酰氟。干血斑(DBS)采样可能为药物发现中啮齿动物研究的样品采集和储存提供一种替代的前体药物稳定方法。
选择了同一母体化合物的两种已知在啮齿动物血液中表现出体外不稳定性的不同前体药物,用于评估DBS对分析物的稳定作用。每种前体药物分别加入新鲜大鼠乙二胺四乙酸(EDTA)全血中,并通过三种方式制备:从液体全血中制备并作为裂解物进行分析;将全血点样到Whatman 903(®)蛋白保存未处理卡片(903卡片)上;将全血点样到Whatman FTA(®)洗脱微量处理卡片(目前称为DMPK - B卡片,FTA卡片)上。加样后0、2、5和24小时以及4、7、14和21天,通过过滤辅助蛋白沉淀法提取样品,并通过超高效液相色谱 - 串联质谱(UHPLC - MS/MS)进行分析。
对于这两种前体药物,通过前体药物的损失和母体的出现确定,在室温下大鼠EDTA全血中DBS卡片上的稳定性至少为21天。用裂解细胞的试剂处理的Whatman FTA洗脱卡片,对于所研究的化合物,并不比Whatman 9(®)蛋白保存未处理卡片更稳定。